Abstract: The present disclosure relates to a novel method for rapid preparation of three dimensional (3D) spheroids/organoids, and the 3D spheroids/organoids prepared by the novel method.

Abstract: The invention provides an assay for identifying a bacterium capable of binding elemental heavy metal, comprising the following steps: cultivating a test bacterium in a suitable first culture medium; immersing at least a surface portion of a test tool into the first culture medium for a second predetermined period of time, said surface portion being coated by elemental heavy metal, respectively; removing said test tool from said first culture medium and optionally rinsing the test tool; contacting a second culture medium with the surface portion coated by elemental heavy metal of said test tool removed in the previous step; and identifying the test bacterium as being capable of binding elemental heavy metal from growth of the test bacterium in said second culture medium.

Abstract: Methods of treating a complex wound by administering to a complex wound in the individual a therapeutically effective amount of a fetal support tissue product to treat the complex wound. Methods of treating a complex lower extremity ulcer by administering to a complex lower extremity ulcer in the individual a therapeutically effective amount of a fetal support tissue product to treat the complex lower extremity ulcer. Methods of reducing or preventing scar formation from granulation tissue by administering a fetal support tissue product to granulation tissue. Methods of repairing a spina bifida defect by administering to the defect in the individual a therapeutically effective amount of an umbilical cord product.

Abstract: The present invention provides a method of manufacturing an animal model of non-alcoholic liver disease by using correlation among metabolic dysregulations through AKT regulation by Hippo signaling, and an animal model prepared by the method above, and a screening method of a therapeutic agent by using the animal model.

Abstract: Application of a fragment of an isolated nucleotide sequence in the construction of zebrafish without intermuscular bones. The nucleotide sequence is shown in SEQ ID NO:1. Gene mutation is performed by taking SEQ ID NO:1 as a target gene; the mutant F0 embryos are selected and cultured to adult fish; F0 mutant is hybridized with wild type zebrafish to generate an F1 embryos; sense mutant heterozygotes F1 is screened out and cultured to adult fish; and then F1 heterozygote self-crosses to generate F2 generation of three gene types, including homozygote, heterozygote, and wild type. Zebrafish without intermuscular bones is obtained by using a gene mutation method, which provided a basis for subsequent research on a molecular formation mechanism of fish intermuscular bones and the cultivation of economic fishes without intermuscular bone and possessed a basic research value and an application value in other economic aquaculture fish species.

Abstract: Provided herein is a drug delivery device and composition, such as a particle, comprising conditioned medium. Also provided herein is a method of preparing polymeric particles for release of conditioned medium. Further, a tissue growth scaffold comprising particles for release of conditioned medium is provided.

Abstract: The present disclosure relates to a light-driven system which is able to chemically modify an organic substrate with high efficiency and in a cost-effective manner. Also provided are methods for chemically modifying an organic substrate using the present systems and methods for manufacturing such systems.

Abstract: Provided is a component having plant defense activity. A PR1 gene expression activator containing a culture of a unicellular alga containing a green photosynthetic pigment as an active ingredient; A plant defense activator containing a culture of a unicellular alga containing a green photosynthetic pigment as an active ingredient; A plant disease preventive or ameliorating agent containing a culture of a unicellular alga containing a green photosynthetic pigment as an active ingredient; and a method of producing a plant defense activating component containing: cultivating a unicellular alga containing a green photosynthetic pigment under an aerobic condition to produce a culture containing an extracellular polysaccharide.

Abstract: The invention concerns the treatment of bioprosthetic tissues a Cyclodextrin, preferably in association with Ethanol.

Abstract: The invention disclosed herein generally relates to methods and systems for converting stem cells into specific tissue(s) or cells through directed differentiation. In particular, the invention disclosed herein relates to methods and systems for promoting functional basal-like cells from pluripotent stem cell-derived lung bud tip progenitor organoid tissue through activation of SMAD signaling via activation of TGF?1 (and/or the TGF? signaling pathway) and BMP4 (and/or the BMP signaling pathway).

Abstract: The present invention relates to an insertable culture container and a kit for three-dimensional cell culture, and a three-dimensional cell co-culture method using the same, the insertable culture container for three-dimensional cell culture comprising: a cylindrical side wall having open upper and lower portions; at least one hook protruding outward from the upper side of the side wall; and at least one support protruding inward from the lower side of the side wall. The present invention is advantageous in that air required for a three-dimensional cell culture structure can be smoothly supplied since the cell is cultured at a position spaced apart from a bottom surface of the culture container, and an existing culture plate can be used without change due to the culture container configured as an insert type.

Abstract: A human amniotic fluid formulation has been developed for topical application to the eye, which is useful for the treatment of ocular diseases and injuries including dry eyes, Sjogren's Syndrome, cataracts, burns and injuries to the eye tissues. The formulation is a sterile de-cellularized human amniotic fluid (D-HAF), devoid of amniotic stem cells and elements of micronized membrane or chorion particles. Methods for treating, or preventing various ocular diseases, injuries and disorders using the formulation, optionally in combination with one or more therapeutic, prophylactic or diagnostic agents are described.

Abstract: Provided subject matter relates to tissue engineering. More specifically provided are kits, devices and methods for in situ repair and regeneration of guided and functional growth of cells and cell components by providing into the injury site biomaterial solution including the cell(s), magnetic particles and solidifying the biomaterial while applying the magnetic field.

Abstract: The present invention relates to methods for deriving multipotent Isl1+ cells (i.e. methods for inducing a cell to enter a multipotent Isl1+ lineage), methods for differentiating Isl1+ cells to cardiac cells, cells obtainable by such methods, kits and compositions for carrying out the methods in accordance with the invention, and also medical applications and pharmaceutical compositions of said cells.

Abstract: Described herein are tissue grafts derived from the placenta with improved physical and biological properties. In one aspect, the tissue graft includes a first membrane comprising Wharton's jelly laminated with amnion, chorion, or a combination thereof. The presence of Wharton's jelly in the grafts enhances the performance of allograft amniotic-derived, caderivic allograft, xenograft, or alloplast soft tissue substitutes.

Abstract: The present invention relates to methods for removing antigens from tissues by sequentially destabilizing and/or depolymerizing cytoskeletal components and removing and/or reducing water-soluble antigens and lipid-soluble antigens. The invention further relates to tissue scaffolding and decellularized extracellular matrix produced by such methods.

Abstract: Microvesicles produced by stem cells grown on a silk scaffold for enhancing stem cell self-renewal/proliferation and promoting tenogenesis in damaged tendons, and their use in tendon wound repair and tendinopathy treatment. Also provided are compositions containing the microvesicles and devices for obtaining them.

Abstract: Novel isolated stem cells derived from pre-term placental tissue and compositions comprising the stem cells are provided as well as use of the compositions for therapy, research and diagnosis. The cells and compositions are useful in treating Myelomeningocele (MCC), spina bifida (SB) or spinal cord injury or paralysis.

Abstract: The invention discloses the use of the Schizochytrium limacinum and its preparation in improving the quality and yield of animal product. The deposit number of Schizochytrium limacinum in the present invention is CGMCC No. 13746 in the China General Microbiological Culture Collection Center. The Schizochytrium limacinum powder produced by the Schizochytrium limacinum may increase the DHA content in an animal product, reduce the cholesterol content in an animal product, and also improve the egg production performance of poultry. This animal product with high DHA content from natural sources is organic, safe, stable, and easy to be absorbed. It may be used as a safer and effective way for people to ingest natural DHA, and it may also cater to and meet consumer needs. Thus, Schizochytrium limacinum and Schizochytrium limacinum powder of the present application have a wide range of application in the field of general food and livestock breeding.

Abstract: Provided is a method of inducing oligodendrocyte precursor cells (OPCs) through direct reprogramming from human somatic cells into which a nucleic acid molecule encoding an Oct4 protein or Oct4 protein-treated human somatic cells. The method of inducing OPCs by treating Oct4-overexpressing human somatic cells with a low molecular weight substance may establish OPCs with high efficiency in a short period of time through direct reprogramming without via neural stem cells, and thus the OPCs are useful as a cell therapeutic agent for an intractable demyelinating disease.